CL2023002204A1 - Agonistas del receptor gpcr, composiciones farmacéuticas que los comprenden y métodos para su uso - Google Patents
Agonistas del receptor gpcr, composiciones farmacéuticas que los comprenden y métodos para su usoInfo
- Publication number
- CL2023002204A1 CL2023002204A1 CL2023002204A CL2023002204A CL2023002204A1 CL 2023002204 A1 CL2023002204 A1 CL 2023002204A1 CL 2023002204 A CL2023002204 A CL 2023002204A CL 2023002204 A CL2023002204 A CL 2023002204A CL 2023002204 A1 CL2023002204 A1 CL 2023002204A1
- Authority
- CL
- Chile
- Prior art keywords
- methods
- pharmaceutical compositions
- receptor agonists
- gpcr receptor
- gpcr
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 abstract 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
En la presente descripción se proporcionan compuestos moduladores del receptor de GLP-1, composiciones farmacéuticas, métodos para su preparación y métodos para su uso en tratamiento y/o diagnóstico.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163143025P | 2021-01-28 | 2021-01-28 | |
US202163183612P | 2021-05-03 | 2021-05-03 | |
US202163274893P | 2021-11-02 | 2021-11-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2023002204A1 true CL2023002204A1 (es) | 2024-03-01 |
Family
ID=80447497
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2023002204A CL2023002204A1 (es) | 2021-01-28 | 2023-07-26 | Agonistas del receptor gpcr, composiciones farmacéuticas que los comprenden y métodos para su uso |
Country Status (13)
Country | Link |
---|---|
US (1) | US20230089073A1 (es) |
EP (1) | EP4284795A1 (es) |
JP (1) | JP2024505250A (es) |
KR (1) | KR20230152011A (es) |
AU (1) | AU2022212019A1 (es) |
BR (1) | BR112023015045A2 (es) |
CA (1) | CA3209593A1 (es) |
CL (1) | CL2023002204A1 (es) |
CO (1) | CO2023011071A2 (es) |
CR (1) | CR20230330A (es) |
EC (1) | ECSP23057029A (es) |
IL (1) | IL304521A (es) |
WO (1) | WO2022165076A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2023001311A (es) | 2020-08-06 | 2023-04-18 | Gasherbrum Bio Inc | Agonistas heterociclicos de glp-1. |
EP4204415A1 (en) | 2020-08-28 | 2023-07-05 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
WO2023057414A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
WO2023057429A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
CA3233131A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes as glp-1 receptor modulators |
WO2023111144A1 (en) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
WO2023111145A1 (en) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
CN117362282A (zh) * | 2022-07-07 | 2024-01-09 | 杭州德睿智药科技有限公司 | Glp-1r激动剂的盐及其制备方法和应用 |
WO2024017266A1 (zh) * | 2022-07-18 | 2024-01-25 | 德睿智药(苏州)新药研发有限公司 | 一种glp-1r激动剂的多晶型物及其制备方法与用途 |
WO2024026338A1 (en) * | 2022-07-27 | 2024-02-01 | Carmot Therapeutics, Inc. | N-heterocylic gpcr receptor agonists, pharmaceutical compositions comprising the same, and methods for their use |
WO2024051700A1 (zh) * | 2022-09-05 | 2024-03-14 | 德睿智药(苏州)新药研发有限公司 | 作为glp1r激动剂的新型芳基氘代苄醚取代杂环类化合物 |
WO2024051749A1 (zh) * | 2022-09-06 | 2024-03-14 | 德睿智药(苏州)新药研发有限公司 | 一种glp-1r激动剂化合物的多晶型物及其制备方法与用途 |
WO2024102625A1 (en) | 2022-11-11 | 2024-05-16 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
WO2024107781A1 (en) | 2022-11-16 | 2024-05-23 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2934789T3 (es) * | 2016-12-16 | 2023-02-27 | Pfizer | Agonistas del receptor glp-1 y usos del mismo |
CA3045644C (en) * | 2018-06-13 | 2024-01-16 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
PE20211871A1 (es) * | 2018-11-22 | 2021-09-21 | Qilu Regor Therapeutics Inc | Agonistas de glp-1r y usos de los mismos |
KR102344561B1 (ko) * | 2019-11-15 | 2021-12-29 | 일동제약(주) | Glp-1 수용체 작용제 및 이의 용도 |
-
2022
- 2022-01-27 CR CR20230330A patent/CR20230330A/es unknown
- 2022-01-27 JP JP2023546234A patent/JP2024505250A/ja active Pending
- 2022-01-27 WO PCT/US2022/014156 patent/WO2022165076A1/en active Application Filing
- 2022-01-27 KR KR1020237029178A patent/KR20230152011A/ko unknown
- 2022-01-27 AU AU2022212019A patent/AU2022212019A1/en active Pending
- 2022-01-27 BR BR112023015045A patent/BR112023015045A2/pt unknown
- 2022-01-27 US US17/586,751 patent/US20230089073A1/en not_active Abandoned
- 2022-01-27 EP EP22704219.9A patent/EP4284795A1/en active Pending
- 2022-01-27 CA CA3209593A patent/CA3209593A1/en active Pending
-
2023
- 2023-07-17 IL IL304521A patent/IL304521A/en unknown
- 2023-07-26 CL CL2023002204A patent/CL2023002204A1/es unknown
- 2023-07-27 EC ECSENADI202357029A patent/ECSP23057029A/es unknown
- 2023-08-24 CO CONC2023/0011071A patent/CO2023011071A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
ECSP23057029A (es) | 2023-10-31 |
CR20230330A (es) | 2023-11-15 |
KR20230152011A (ko) | 2023-11-02 |
CA3209593A1 (en) | 2022-08-04 |
BR112023015045A2 (pt) | 2023-10-03 |
CO2023011071A2 (es) | 2023-11-10 |
US20230089073A1 (en) | 2023-03-23 |
IL304521A (en) | 2023-09-01 |
AU2022212019A1 (en) | 2023-08-03 |
WO2022165076A1 (en) | 2022-08-04 |
EP4284795A1 (en) | 2023-12-06 |
JP2024505250A (ja) | 2024-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2023011071A2 (es) | Agonistas del receptor gpcr, composiciones farmacéuticas que los comprenden y métodos para su uso | |
DOP2023000016A (es) | Macrociclos como moduladores del regulador de conductancia transmembrana de la fibrosis quística, composiciones farmacéuticas de estos, su uso en el tratamiento de la fibrosis quística y procesos para elaborarlos | |
CL2020002866A1 (es) | Compuestos de heteroaril tetracíclicos | |
CL2017003436A1 (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso | |
CL2019000510A1 (es) | Adenovirus armado con un activador de células t biespecífico (bite). | |
ES2969049T3 (es) | Antagonista de IL-4R para uso en un método para tratar o prevenir el asma | |
BR112023022836A2 (pt) | Agonistas de receptores de glp-1 benzimidazoíla, composições farmacêuticas que compreendem os mesmos e métodos para seu uso | |
CL2018000883A1 (es) | Moduladores del receptor x farnesoide | |
ECSP077349A (es) | Nuevos derivados de sulfonamida como moduladores del receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias | |
BR112016028961A8 (pt) | fibras eletrotorcidas, seu método de preparação e seu uso, bem como composição, e kit | |
CL2011003160A1 (es) | Compuestos derivados de heterociclicos, moduladores cb2; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades reumaticas, autoinmune, inflamatorias, dolor, entre otras. | |
ECSP21038390A (es) | Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr | |
CO2017011017A2 (es) | Azabenzimidazoles y su uso como moduladores del receptor ampa | |
CL2022000998A1 (es) | Inhibidores de las cinasas raf | |
CL2010001538A1 (es) | Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de las proteinas quinasas; composicion farmaceutica; y su uso para el tratamiento del cancer, o un trastorno proliferativo celular. | |
CL2008003789A1 (es) | Compuestos derivados de bencimidazol sustituido por carboxilo o por hidroxilo, moduladores selectivos del receptor x de farnesoide (fxr); proceso de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la diabetes, dislipidemia, sindrome metabolico, cancer, alzheimer. | |
ECSP077323A (es) | Nuevos derivados de sulfonamida como moduladores del receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias | |
UY28870A1 (es) | Derivados heterocíclicos, composiciones y proceso de preparación | |
ECSP088584A (es) | Nuevos derivados de benzimidazol como inhibidores del receptor vanilloide 1 (vrl) | |
CL2019001991A1 (es) | Moduladores del receptor de estrógeno. | |
CL2009000084A1 (es) | Compuestos derivados de sulfonamida sustituida, moduladores de receptores de bradiquinina; composicion farmaceutica que contiene a los compuestos; y uso en el tratamiento del dolor agudo, neuropatico o cronico, entre otros. | |
CO6280470A2 (es) | Bis-piridilpiridonas como antaginistas del receptor 1 de la hormona concentradora de la melanina | |
CO2022006466A2 (es) | Inhibidores de egfr alostéricos y métodos de uso de los mismos | |
CL2020003447A1 (es) | Composiciones y métodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas | |
CO2022008817A2 (es) | Macrociclos para uso en el tratamiento de enfermedades |